Home
About us
Team
Portfolio
Stories
ESG & Impact
News
Contact
News
From investments to outcomes, stay connected to the people and companies transforming Healthtech with us.
Compagnie:
Fund:
Lauxera Capital Partners supports Matrix One’s strategic expansion with two acquisitions, strengthening its life sciences software platform
Lauxera Capital Partners supports Matrix One’s strategic expansion with two acquisitions, strengthening its life sciences software platform
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Terumo to acquire OrganOx Limited, a leading innovator in organ preservation devices, marking strategic entry into the organ transplantation-related sector
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
Oxford university spinout OrganOx sold to Japanese group Terumo for $1.5bn
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital
La cession d’Organox à un industriel offre une première sortie éclatante à Lauxera Capital
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
OrganOx réalise l’une des plus importantes sorties de fonds dans le secteur des technologies médicales au Royaume-Uni, générant un rendement record pour BGF
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Terumo Buying Organ Tech Provider OrganOx for$1.5 Billion
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera Capital Partners cède OrganOx pour 1,5 Md $
Lauxera enregistre sa première sortie
Lauxera enregistre sa première sortie
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Terumo to acquire Organox Limited for approximately USD $1.5 billion
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners is proud to announce its investment in Antaros, a leading Swedish Imaging Drug Development Partner
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Capital Partners Co-Leads a $142m Equity Investment Into OrganOx
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Invests €50m in Acandis, a German, Neurovascular Medical Device Company Dedicated to the Prevention and Treatment of Stroke
Lauxera Capital Partners Acquires Galen Data
Lauxera Capital Partners Acquires Galen Data
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Synovo Group secures €12 million funding from Lauxera Capital Partners to accelerate growth and innovation in Healthtech transport software
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural cycles: $55m to consolidate its leadership in digital contraceptive health
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Natural Cycles Closes $55m Series C Financing Round Led by Lauxera Capital Partners
Newsweek: World’s Best Digital Health Companies 2024
Newsweek: World’s Best Digital Health Companies 2024
OSPI wants to optimize the use of hospital data with AI
OSPI wants to optimize the use of hospital data with AI
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Creation of Ospi, the result of the merger between Groupe PSIH and Collective Thinking
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners invests €17 million in Swedish regenerative medicine leader BioLamina AB
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Lauxera Capital Partners has led a £25m growth investment into OrganOx
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Caresyntax, Relyens and Intel are collaborating to launch the Connected Surgery program
Purification: Auvergne, France-based Verdot changes hands
Purification: Auvergne, France-based Verdot changes hands
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Lauxera Capital Partners invests €10m in German Medtech software company Matrix Requirements
Leading MedTech Lifen raises €50M
Leading MedTech Lifen raises €50M
Caresyntax Extends Series C to Total Raise of $130 million
Caresyntax Extends Series C to Total Raise of $130 million
Press Release Groupe PSIH
Press Release Groupe PSIH
Sifted – Caresyntax secures $100m for AI hospital operating tech
Sifted – Caresyntax secures $100m for AI hospital operating tech
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Healthtech – Caresyntax hauls in $100m to expand
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
Fierce Biotech – LUMICKS snags £93M for its molecular tweezers and cell therapy hardware
Lauxera Capital Partners appoints Dr. Oern Stuge as Senior Advisor – Press release
Lauxera Capital Partners appoints Dr. Oern Stuge as Senior Advisor – Press release
Lauxera raises over €400 million to support the global expansion of European healthtechs
Lauxera raises over €400 million to support the global expansion of European healthtechs
Lauxera raises over €400m for its second vintage
Lauxera raises over €400m for its second vintage
Lauxera tops target for sophomore fund
Lauxera tops target for sophomore fund
Impact and financial returns: a winning combination
Impact and financial returns: a winning combination
Pierre Moustial on BFM Business – Check-up Santé
Pierre Moustial on BFM Business – Check-up Santé
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera’s charitable partnership with Institut Imagine is explained in this interview with Stanislas Lyonnet and Pierre Moustial
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
Lauxera Capital Partners signs a partnership with Institut Imagine to fund groundbreaking research into rare diseases
Lauxera Capital Partners – Press release – Final closing
Lauxera Capital Partners – Press release – Final closing
Pierre Moustial Interview
Pierre Moustial Interview
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Biomedicaments : Verdot to invest €10 million in new plant in Puy-de-Dôme
Impact and financial returns: a winning combination